Global spine biologics market to hit $2.7B by 2024 — 18 key players

Written by Jackie Drees | January 30, 2019 | Print  |

The global spine biologics market is expected to reach $2.7 billion by 2024, increasing at a 4.4 percent compound annual growth rate, according to a Data Bridge Market Research report.

Here are 18 key market players:

1. Arthrex
2. Cesca Therapeutics
3. DePuy Synthes
4. DMP Spine
5. Exactech
6. K2M
7. Lattice Biologics
8. Medtronic
9. Nuo Therapeutics
10. NuTech
11. NuVasive
12. Orthofix Holdings
13. Regen Lab SA
14. RTI Surgical
15. Stryker
16. Wright Medical Technology
17. Xtant Medical Holdings
18. Zimmer Biomet

More articles on biologics:
U of Missouri to release biojoint records amid allegations of false marketing: 5 things to know
Japan approves stem cell treatment for SCI — Some researchers doubt efficacy
Clinical trial proves stem cells effective to treat spinal cord injuries: 5 notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months